Pioglitazone prevented the neointimal hyperplasia at the site of anastomosis
Project/Area Number |
20591646
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Thoracic surgery
|
Research Institution | Kobe University |
Principal Investigator |
OKADA Kenji Kobe University, 医学部附属病院, 特命准教授 (90284356)
|
Co-Investigator(Kenkyū-buntansha) |
OKITA Yutaka 神戸大学, 医学(系)研究科(研究院), 教授 (40322193)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 心臓血管外科学 / 小口径人工血管 / ピオグリタゾン / 吻合部狭窄 |
Research Abstract |
Small caliber (〓2mm) prosthetic graft for coronary artery bypass grafting has not been developed for clinical use. The major cause of sticking point is the neointimal hyperplasia at the site of anastomosis. In the current study, we used a rat aortic interposition model with autologous femoral vein. Oral dose of Pioglitazone successfully prevented graft degeneration including the neointimal hyperplasia at the anastomosis. We are now under investigation for the prevention of neointimal hyperplasia at the anastomosis of small-caliber vascular prosthesis.
|
Report
(4 results)
Research Products
(5 results)